Biomedical Engineering Reference
In-Depth Information
7. Reiter EO, Attie KM, Moshang TJ, Silverman BL, Kemp SF,
Neuwirth RB, et al. (2001) A multicenter study of the efficacy
and safety of sustained release GH in the treatment of naive
pediatric patients with GH deficiency. J. Clin. Endocrinol.
Metab. 86, 4700-4706.
8. Cook DM, Biller BMK, Vance ML, Hoffman AR, Phillips LS,
Ford KM, et al. (2002) The pharmacokinetic and pharmaco-
dynamic characteristics of a long-acting growth hormone (GH)
preparation (Nutropin Depot) in GH-deficient adults. J. Clin.
Endocr. Metab. 87, 4508-4514.
9. Jostel A, Mukherjee A, Alenfall J, Smethurst L, Shalet SM.
(2005) A new sustained release preparation of human growth
hormone and its pharmacokinetic, pharmacodynamic and
safety profile. Clin. Endocrinol. 62, 623-627.
10. Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth
RB, Ford KM. (2002) A long-acting growth hormone
(Nutropin Depot): efficiency and safety following two years
of treatment in children with growth hormone deficiency.
J. Pediatr. Endocrinol. Metab. 15, 715-722.
11. Kemp SK, Fielder PJ, Attie KM, Blethen SL, Reiter EO, Ford
KM, et al. (2004) Pharmacokinetic and pharmacodynamic
characteristics of long-acting growth hormone (GH) prepara-
tion (Nutropin Depot) in GH deficient children. J. Clin.
Endocr. Metab. 89, 3234-3240.
12. Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen
G, et al. (2002) Albutropin: a growth hormone-albumin fusion
with improved pharmacokinetics and pharmacodynamics in
rats and monkeys. Eur. J. Pharmacol. 456, 149-158.
13. Wilkinson IR, Ferrandis E, Artymiuk PJ, Teillot M, Soulard C,
Touvay C, et al. (2007) A ligand-receptor fusion of growth
hormone forms a dimer and is a potent long-acting agonist.
Nat. Med. 13, 1108-1113.
14. Ferrandis E, Pradhananga SL, Touvay C, Kinoshita C, Wil-
kinson IR, Stafford K, et al.
toxicology, pharmacokinetics and pharmacodynamics of
growth hormone ligand-receptor
fusions. Clin. Sci. 119,
483-491.
15. Baumann G, Amburn KD, Buchanan TA. (1987) The effect of
circulating growth hormone-binding protein on metabolic
clearance, distribution, and degradation of human growth
hormone. J. Clin. Endocrinol. Metab. 64, 657-660.
16. Baumann G. (1991) Growth hormone heterogeneity: genes,
isohormones, variants, and binding proteins. Endocr. Rev. 12,
424-449.
17. Baumann G, Shaw MA, Buchanan TA. (1989) In vivo kinetics
of a covalent growth hormone-binding protein complex.
Metabolism 38, 330-333.
18. Clark RG, Mortensen DL, Carlsson LM, Spencer SA, McKay P,
MulkerrinM, et al. (1996) Recombinant human growth hormone
(GH)-binding protein enhances the growth-promoting activity
of human GH in the rat. Endocrinology 137, 4308-4315.
19. Baumann G. (1995) Growth hormone binding protein-errant
receptor or active player? Endocrinology 136, 377-378.
20. Ayling RM, Ross R, Towner P, Von Laue S, Finidori J,
Moutoussamy S, (1997) A dominant-negative mutation of
the growth hormone receptor causes familial short stature.
Nat. Genet. 16, 13-14.
21. Ross RJ, Esposito N, Shen XY, Von Laue S, Chew SL, Dobson
PR, et al. (1997) A short isoform of the human growth hormone
receptor functions as a dominant negative inhibitor of the full-
length receptor and generates large amounts of binding protein.
Mol. Endocrinol. 11, 265-273.
22. de Vos AM, Ultsch M, Kossiakoff AA. (1992) Human growth
hormone and extracellular domain of its receptor: crystal
structure of the complex. Science 255, 306-312.
23. Mordenti J, Chen SA,Moore JA, FerraioloBL, Green JD. (1991)
Interspecies scaling of clearance and volume of distribution data
for five therapeutic proteins. Pharm. Res. 8, 1351-1359.
(2010)
Immunogenicity,
Search WWH ::
Custom Search